Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorWritten by Jeffrey Neal Johnson. Published: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector is experiencing renewed volatility amid AI-driven scare trades and valuation concerns, a different narrative is playing out in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs — roughly $245 per share — creating a divergence that has attracted Wall Street attention. This rally runs counter to the perception of the healthcare giant as a slow-moving, "boring" stock. Over the last 30 days, shares have climbed roughly 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional capital is rotating out of riskier assets and paying up for stability, predictable cash flow, and strong operational execution. On Feb. 24, 2026, Johnson & Johnson goes ex-dividend. The stock price will likely drop by the forthcoming dividend amount, $1.30 per share — a mechanical market adjustment rather than a signal of deteriorating business performance. For income-focused investors, this technical dip often presents an attractive entry point rather than a reason to sell. 64 Years of Unbroken Growth The central case for holding Johnson & Johnson during turbulent markets is its financial resilience and role as a portfolio stabilizer. The company is part of an elite group of equities known as Dividend Kings, firms that have increased their dividend for at least 50 consecutive years. Johnson & Johnson has now raised its dividend for 64 consecutive years, a track record spanning recessions, market crashes, and geopolitical shocks. That consistency is rare in a market focused on speculative growth. The stock yields about 2.12%, based on an annual payout of $5.20 per share. While higher yields exist in bonds or riskier sectors, J&J offers a blend of income and safety. The dividend is backed by a sizable liquidity cushion: management projects free cash flow near $21 billion in 2026. That level of cash generation supports dividend payments, R&D investment, and legal expenses without heavy reliance on debt. For risk-averse investors, another compelling metric is the stock's Beta, which measures sensitivity to the broader market (S&P 500). Johnson & Johnson's Beta is about 0.35, meaning the stock has historically been roughly 65% less volatile than the market. When tech names swing wildly, J&J tends to hold its ground. Adding JNJ to a tech-heavy portfolio can act as a mathematical shock absorber, reducing overall volatility while retaining equity exposure. Beyond the Patent Cliff: The Road to $100 Billion Contrary to the idea that "safe" stocks can't grow, Johnson & Johnson is executing a strategic pivot that's producing results. Management has issued strong guidance for 2026, projecting full-year revenue to surpass $100 billion for the first time in company history and forecasting adjusted EPS of around $11.53. That progress is driven by the reinvention of its pharmaceutical division, now branded as Innovative Medicine. Investors once feared a steep decline after Stelara, a blockbuster immunology drug, lost exclusivity in 2025. Instead of a collapse, J&J has offset that pressure with new, high-performing therapies. Two key assets are driving this resilience: - Darzalex: An oncology workhorse producing roughly $14 billion in annual sales, Darzalex has established J&J as a leader in multiple myeloma treatment.
- Tremfya: Poised as a successor to Stelara, Tremfya recently reported strong three-year data showing durable remission rates for ulcerative colitis — evidence the company can defend market share in immunology as older drugs fade.
The Tech in MedTech: High-Margin Technologies Growth extends beyond pharmaceuticals into MedTech, which has shifted focus toward high-growth, high-margin technologies. A notable example is Shockwave Medical, acquired to modernize the cardiovascular portfolio. Shockwave's intravascular lithotripsy (IVL) technology uses sonic pressure waves to break up calcified plaque in arteries — akin to treatments for kidney stones — and represents a significant improvement over traditional angioplasty balloons. Combined with existing heart pump and surgical businesses, this technology strengthens J&J's cardiovascular franchise. Johnson & Johnson is also advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals a bid to compete in the growing soft-tissue robotics market. These high-tech devices carry higher profit margins and tend to build long-term relationships with hospital systems, providing an earnings tailwind beyond low-margin consumables. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is reshaping the company's footprint. A major development is the potential separation or sale of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports suggest the company is exploring a large-scale sale. Divesting orthopedics would be an "addition by subtraction." Orthopedics is a mature, lower-growth segment compared with booming oncology and cardiovascular businesses. Selling the unit could boost overall revenue growth rates and profit margins, while generating a substantial one-time cash influx to fund acquisitions or share repurchases. No analysis of Johnson & Johnson is complete without acknowledging legal risk. The company faces ongoing talc litigation, highlighted by a recent $1.5 billion verdict, and a commercial dispute with Bayer over prostate cancer marketing claims. Nonetheless, the stock's rally indicates investors are looking beyond headline noise. Many bulls argue J&J has the financial resources to manage these liabilities without disrupting operations. With more than $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and roughly $21 billion in annual free cash flow, the company appears financially equipped to absorb settlements — making legal matters a balance-sheet item rather than an existential threat to the dividend or the business. Capital Preservation With Upside Johnson & Johnson has evolved from a sprawling conglomerate into a more focused, high-tech healthcare company. After spinning off its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, the firm is concentrating on higher-growth opportunities in pharmaceuticals and medical technology. Though JNJ trades near all-time highs and is no longer a deep-value bargain, it offers a compelling mix of capital preservation and upside. A 64-year dividend growth streak, a very low volatility profile, and a credible path to $100 billion in revenue make the stock an attractive option for 2026. For investors fatigued by technology-sector unpredictability, Johnson & Johnson demonstrates that, in the current market, "boring" can be both beautiful and profitable.
| 
